openPR Logo
Press release

PTSD Exhibits Emerging Pipeline with 23 Drug Candidates

06-21-2017 02:14 PM CET | Health & Medicine

Press release from: P&S Market Research - Pharmaceuticals

The study analysed that the PTSD pipeline comprises of 23 drug candidates, of which one drug candidate is in the Phase III stage of development, two drug candidates are in the Phase II stage of development, seven drug candidates are in the Pre-Clinical stage of development, two drug candidates are in Discovery stage, one drug candidate is in Unknown Clinical stage, one drug candidate is in the Discontinued stage and nine drug candidates are Inactive. PTSD (PTSD) is a neurological disorder that develops in people who have experienced a scary or a dangerous event. PTSD can occur in a person at any age. According to the National Center of PTSD, around seven to eight out of 100 individuals experience PTSD at some point in their lives. Most of the people recover from traumatic situation naturally, but those who continue to experience problems are diagnosed with PTSD. People with PTSD are used to feel frightened even when they are not in a dangerous situation. PTSD generally occurs more often in women than men. Various collaboration between educational institutes, associations, and pharma companies are driving the therapeutic pipeline of PTSD.

Browse Report Description at: www.psmarketresearch.com/market-analysis/ptsd-therapeutics-pipeline-analysis

As per the findings of the research, around 46.0% of drug candidates of PTSD pipeline are being developed to be administered by the oral route, 15.0% are being developed to be administered by the sublingual route, 8.0% are being developed to be administered by the topical route, 8.0% are being developed to be administered by another route or others and 23.0% are being developed to be administered by routes that are not disclosed.

Explore Report Sample at: www.psmarketresearch.com/market-analysis/ptsd-therapeutics-pipeline-analysis/report-sample

Most of the pharmaceutical companies are developing PTSD drug candidates that are present in the different phases of development. For instance, Tonix Pharmaceuticals Holding Corp. has its drug candidate in the Phase III stage of development, Azevan Pharmaceuticals, Inc. has its drug candidate in the Phase II stage of development.

Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals

Other key players developing drugs for the treatment of PTSD include One World Cannabis Ltd., Axim Biotechnologies, Inc., F. Hoffman-La-Roche AG, Therapade Technologies LLC, Neurocrine Biosciences, Inc. and Purdue Pharma L.P.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-Free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release PTSD Exhibits Emerging Pipeline with 23 Drug Candidates here

News-ID: 590124 • Views: 397

More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where
Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market As per the findings of research, it

All 5 Releases


More Releases for PTSD

Post-Traumatic Stress Disorder (PTSD) Therapeutics Pipeline Analysis Report
The study analysed that the PTSD pipeline comprises of 23 drug candidates in different stages of development. PTSD is a neurological disorder that develops in people who have experienced a scary or a dangerous event. PTSD can occur in a person at any age. According to the National Center of PTSD, around seven to eight out of 100 individuals experience PTSD at some point in their lives. Most of the
Post Traumatic Stress Disorder (PTSD) Therapeutics Market to Remain Lucrative Du …
Post-traumatic stress disorder (PTSD) is a psychological condition that occurs in individuals of any age and gender. Its symptoms can show up immediately after a traumatic experience or with the course of time. It is one of the most common psychological disorders, affecting about 8 mn adult Americans and an annual incidence rate of close to 3.5% across the globe. Its first line of treatments includes counseling and psychotherapy. The
Worldwide Analysis on Post-Traumatic Stress Disorder (PTSD) Therapeutics Market …
Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market: Overview Post-traumatic stress disorder (PTSD) is a psychological condition that occurs in individuals of any age and gender. Its symptoms can show up immediately after a traumatic experience or with the course of time. It is one of the most common psychological disorders, affecting about 8 mn adult Americans and an annual incidence rate of close to 3.5% across the globe. Its first line
Post-Traumatic Stress Disorder (PTSD) - Pipeline Insight and Therapeutic Assessm …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Post-Traumatic Stress Disorder (PTSD)-Pipeline Insight, 2017” to its report offerings. The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1265521 The report provides comprehensive insights of the ongoing therapeutic research and development across Post-Traumatic Stress Disorder (PTSD). The report provides a complete understanding of the
Donald Trump And PTSD: PTSD Is Not A Sign Of Weakness Says June Sitler, Author O …
PTSD can take many forms. When one hears Post Traumatic Stress Disorder (PTSD) the image of a Vietnam Vet comes to mind. However, many people from all walks of life may suffer from this disorder. They are the survivors. They can be people who live in the inner city, those who have suffered the loss of a loved one, survivors of childhood trauma in adulthood, or a man or woman
Heal My PTSD Launches Virtual PTSD Support Groups
FOR IMMEDIATE RELEASE Contact: Michele Rosenthal Michele@healmyptsd.com 561.531.1405 Heal My PTSD Launches Virtual PTSD Support Groups January 17, 2011 – Self-Empowered Healing Coach, Michele Rosenthal, founder of www.healmyptsd.com, will launch virtual PTSD support groups for both survivors and caregivers on February 7, 2011. Conducted via a telephone conference line, these groups will be the first of their kind to provide a live support forum for survivors and